SavedAdd your journal

Journals / art / 2020 / Cilt: 35 - Sayı: 3

Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis

Kemal EROL
Ragıp ERTAŞ
Journal
art
Pages
440–442
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis.
📊
Key Findings & Data:Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis.
💡
Conclusion & Impact:In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.

🔖

Cite This Article

EROL, K., ERTAŞ, R. (2020). Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis. art, Cilt: 35 - Sayı: 3, 440–442. https://ajindex.com/articles/144884

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Azevedo A, Torres T. Tofacitinib: A New Oral Therapy for Psoriasis. Clin Drug Investig 2018;38:101-12.
  2. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
  3. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-a agents. Autoimmun Rev 2014;13:15-9.
  4. Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kózka M. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 2017;14:15-29.
  5. Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Therapy Lett 2018;23:5-9.
  6. Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71:70-4.
  7. Gök K, Cengiz G, Erol K, Ozgocmen S. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Acta Reumatol Port 2017;42:88-90.
  8. Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, et al. Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis 2016;75:2214-6.
  9. Pollard KM, Cauvi DM, Toomey CB, Morris KV, Kono DH. Interferon-g and systemic autoimmunity. Discov Med 2013;16:123-31.
  10. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-7.